Antibiotics are used in sick people. They are profitable drugs and being actively developed. There was a lull in new antibiotic drug development, because the existing ones worked fine. That is changing.
Actually, they're not profitable (not even close) and no they're not being actively developed as they result in huge losses as they're not used in chronic patients (10-14 days max on a €1-5B investment leads to crappy fiscal returns.) Over here, the only viable solution being discussed is nationalised screening and production.
FWIW, this is my current major research avenue.